激素受体阳性/HER2阴性转移性乳腺癌连续内分泌治疗疗效的真实世界多中心全国研究
该研究基于法国ESME项目,纳入2008至2014年间18个综合癌症中心启动系统治疗的9921例HR+/HER2-转移性乳腺癌患者,评估多线内分泌治疗±靶向治疗的疗效。主要终点为连续无进展生存期(PFS),一线、二线、三线内分泌治疗的中位PFS分别为11.5、5.8和5.5个月。多因素分析显示转移复发时间、转移时症状、转移部位数量及位置是PFS1的预后因素,而既往PFS持续时间是后续PFS的唯一预后因素。
要点
- 一线内分泌治疗中位PFS为11.5个月,二线5.8个月,三线5.5个月
- 既往PFS持续时间是后续内分泌治疗PFS的唯一预后因素
- 10%患者对内分泌治疗长期应答,化疗前总治疗时间≥43.6个月
核心结论
- 真实世界中HR+/HER2-转移性乳腺癌患者一线内分泌治疗的中位PFS与临床试验报告相似,二线和三线内分泌治疗的中位PFS分别为5.8和5.5个月。
- 尽管国际共识推荐早期启动内分泌治疗,但多数患者未接受内分泌治疗。
- 肿瘤负荷低的患者可能从内分泌治疗中获得长期应答。
研究设计与样本
- ESME项目分析了2008年至2014年间在18个法国综合癌症中心启动转移性乳腺癌系统治疗的所有患者数据。
- 研究纳入9921例HR+/HER2-转移性乳腺癌患者,主要终点为连续PFS评估。
主要发现
- 在任何化疗前,4195例(43.4%)接受一线内分泌治疗±靶向治疗,1252例(29.8%)接受二线,279例(6.6%)接受三线。
- 一线、二线、三线内分泌治疗±靶向治疗的中位PFS分别为11.5个月(95%CI 10.8-12.1)、5.8个月(95%CI 5.3-6.1)和5.5个月(95%CI 4.6-6.3)。
- 多因素分析显示,诊断至转移复发时间(P<0.0001)、转移复发时症状(P=0.01)、转移部位数量(P=0.0003)及其位置(P<0.0001)是PFS1的预后因素。
- 既往PFS持续时间是后续PFS的唯一预后因素(10%阈值)。
- 10%的患者对内分泌治疗显示长期应答,化疗前总治疗时间≥43.6个月。
临床怎么用
- 对于HR+/HER2-转移性乳腺癌,内分泌治疗应作为初始治疗选择,但真实世界中多数患者未接受。
- 既往内分泌治疗的PFS持续时间可用于预测后续内分泌治疗的获益。
- 肿瘤负荷低的患者可能适合延长内分泌治疗以避免或延迟化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For luminal metastatic breast cancer (MBC), endocrine therapy (ET) is the recommended initial treatment before chemotherapy. Our objective was to evaluate the efficacy of multiple ET lines in a real-life study. METHODS: The Breast Cancer Epidemiological Strategy and Medical Economics (ESME) project analysed data from all patients with systemic treatment for MBC initiated between 2008 and 2014 in one of the 18 French Comprehensive Cancer Centres. The primary end-point was the successive progression-free survival (PFS) evaluation. RESULTS: The ESME research programme included 9921 patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2) negative (HER2-) MBC. Before any chemotherapy, 4195 (43.4%), 1252 (29.8%) and 279 (6.6%) patients received one, two or three ET ± targeted therapy, respectively. The median PFS for first-, second- and third-line ET ± targeted therapy was 11.5 (95% confidence interval [CI], 10.8-12.1), 5.8 (95% CI, 5.3-6.1) and 5.5 (95% CI, 4.6-6.3) months, respectively. In a multivariate analysis, time from diagnosis to metastatic recurrence (P < 0.0001), presence of symptoms at metastatic relapse (P = 0.01), number of metastatic sites (P = 0.0003) and their localisation (P < 0.0001) were prognostic factors for PFS1. Duration of previous PFS was the only prognostic factor for subsequent PFS (10% threshold). Ten percent of the patients showed long-term response to ET, with a total treatment duration before chemotherapy ≥43.6 months. CONCLUSIONS: Median PFS in our HR+/HER2- real-life cohort is similar to median first-line PFS reported in clinical trials, regardless of ET used as second- and third-line treatment. Despite the international consensus on early initiation of ET, the latter is not prescribed in most of the cases. Patients with a low tumour burden may achieve prolonged response on ET.
引用
- Le Saux O, Lardy-Cleaud A, Frank S, et al. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. Eur J Cancer. 2019. PMID: 31330488. doi:10.1016/j.ejca.2019.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。